PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
Turnover
32.23%
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+31.13%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.73B
AUM Growth
+$575M
(+14%)
Cap. Flow
-$244M
Cap. Flow
% of AUM
-5.15%
Top 10 Holdings %
Top 10 Hldgs %
46.08%
Holding
127
New
17
Increased
23
Reduced
25
Closed
19
Avg Time Held Equity + Options
1.9
years
Top 10 Avg Time Held Equity + Options
1.6
years
Top 20 Avg Time Held Equity + Options
1.5
years
Avg Time Held Equity only
2
years
Top 10 Avg Time Held Equity only
1.6
years
Top 20 Avg Time Held Equity only
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VRNA
Verona Pharma
VRNA
|
+$95.5M |
| 2 |
Viking Therapeutics
VKTX
|
+$57.4M |
| 3 |
argenx
ARGX
|
+$52.2M |
| 4 |
Adagio Medical Holdings
ADGM
|
+$46.7M |
| 5 |
Oruka Therapeutics
ORKA
|
+$43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$441M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$74.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$60M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$38.8M |
| 5 |
SpringWorks Therapeutics
SWTX
|
+$35.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.6% |
| 2 | Miscellaneous | 1.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $798K | 0.02% |
50,896
-20,000
| -28% | -$178K |
2021 Q2
13 quarters
|
|
102
Kyverna Therapeutics
KYTX
$355M
| $734K | 0.02% |
150,000
| – | – |
2024 Q1
2 quarters
|
|
103
DELISTED
Forte Biosciences
FBRX
| $535K | 0.01% |
95,742
-34,872
| -27% | -$359K |
2023 Q3
4 quarters
|
|
104
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $251K | 0.01% |
116,754
| – | – |
2024 Q1
2 quarters
|
|
105
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $170K | ﹤0.01% |
100,000
-22,643
| -18% | -$69K |
2020 Q4
15 quarters
|
|
106
Revolution Medicines Inc Warrant
RVMDW
$111M
| $35K | ﹤0.01% |
250,000
| – | – |
2023 Q4
3 quarters
|
|
107
DELISTED
Surrozen Inc Warrant
SRZNW
| $1.72K | ﹤0.01% |
166,666
| – | – |
2021 Q3
12 quarters
|
|
|
108
DELISTED
CareMax, Inc. Warrant
CMAXW
| $594 | ﹤0.01% |
60,000
| – | – |
2021 Q2
13 quarters
|
|
109
Axogen
AXGN
$2.08B
| – | – |
-30,421
| Closed | -$220K | – |
|
110
BridgeBio Pharma
BBIO
$12.7B
| – | – |
-1,215,346
| Closed | -$30.8M | – |
|
111
Cabaletta Bio
CABA
$264M
| – | – |
-585,045
| Closed | -$4.38M | – |
|
112
Cullinan Oncology
CGEM
$882M
| – | – |
-749,916
| Closed | -$13.1M | – |
|
113
enGene Therapeutics
ENGN
$106M
| – | – |
-800,000
| Closed | -$7.54M | – |
|
114
Foghorn Therapeutics
FHTX
$110M
| – | – |
-544,000
| Closed | -$3.13M | – |
|
115
CALL
Immunovant
IMVT
$5.81B
| – | – |
-200,000
| Closed | -$5.28M | – |
|
116
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-500,000
| Closed | -$5.89M | – |
|
|
117
Madrigal Pharmaceuticals
MDGL
$10.6B
| – | – |
-264,600
| Closed | -$74.1M | – |
|
118
Recursion Pharmaceuticals
RXRX
$1.99B
| – | – |
-769,230
| Closed | -$5.77M | – |
|
119
ARS Pharmaceuticals
SPRY
$401M
| – | – |
-867,319
| Closed | -$7.38M | – |
|
120
Tactile Systems Technology
TCMD
$500M
| – | – |
-62,639
| Closed | -$748K | – |
|
121
State Street SPDR S&P Biotech ETF
XBI
$9.74B
| – | – |
-22,665
| Closed | -$2.23M | – |
|
122
Skye Bioscience
SKYE
$6.82M
| – | – |
-62,500
| Closed | -$4M | – |
|
123
Tempus AI
TEM
$12.5B
| – | – |
-275,000
| Closed | -$9.63M | – |
|
124
DELISTED
Revance Therapeutics, Inc.
RVNC
| – | – |
-600,000
| Closed | -$1.54M | – |
|
125
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| – | – |
-173,365
| Closed | -$971K | – |
|
Similar funds
QP
RWM
AWA
WHRC
KGA
LSERS
CAG
MCM
Perceptive Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, Perceptive Advisors held 127 positions worth $4.73B, up 14% from $4.15B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $244M in Q3 2024, closing 19 positions and reducing 25 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $441M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Perceptive Advisors opened a new position in Adagio Medical Holdings worth $25.3M.
- Perceptive Advisors's largest Q3 2024 buy was Adagio Medical Holdings: 9,812,419 shares worth $25.3M.
- Perceptive Advisors added most to Verona Pharma in Q3 2024, an estimated $95.5M increase.
- Perceptive Advisors's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $60M.
- Perceptive Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $441M.
- Perceptive Advisors's ten largest holdings make up 46% of its $4.73B portfolio in Q3 2024.
- Perceptive Advisors opened 17 new positions and closed 19 in Q3 2024.
- Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $4.73B.
Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.